A Phase IB Study of BI 894999 for People with Advanced NUT Cancer


Full Title

An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies With Repeated Administration in Patients With Clinical Benefit


The purpose of this study is to assess the safety of the investigational drug BI 894999 in people with a rare form of aggressive cancer called NUT carcinoma. This cancer can develop anywhere in the body, but it often appears in the head, neck, or lungs. BI 894999 is designed to stop tumor growth by blocking a protein called BRD, which promotes the growth of NUT cancer cells. BI 894999 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic NUT carcinoma that cannot be successfully treated using other therapies.
  • Patients should recover from the serious side effects of prior therapies before receiving BI 894999.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 15 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Paul Paik at 646-608-3759.